Nanalysis Sci Stock Price, News & Analysis

Nanalysis Scientific Corp. (NSCIF) has announced the grant of 335,000 stock options to its Directors and Officers, allowing them to purchase shares at $1.10 each for five years. The options will vest over three years, with one-third vesting annually. Additionally, 135,000 Restricted Stock Units (RSUs) were granted to Directors, also vesting over the same period. Nanalysis specializes in portable Nuclear Magnetic Resonance (NMR) spectrometers and has expanded its market presence following the acquisition of K'Prime, enhancing its sales and service capabilities in North America.

Nanalysis Scientific Corp. announces the appointment of Randall McRae as Chief Financial Officer. Previously serving as interim CFO for seven months, McRae brings over 15 years of experience from MNP LLP and co-founding McRally LLP, a cloud accounting firm. His appointment aims to foster company growth and align with Nanalysis's innovative trajectory in portable NMR technology. The company specializes in developing portable Nuclear Magnetic Resonance (NMR) machines for various industries, including oil and gas, pharmaceuticals, and chemicals. Nanalysis aims to capitalize on new global market opportunities through its recent acquisitions and partnerships.

Nanalysis Scientific Corp. reported strong growth in Q3 2022, achieving consolidated revenue of $6,878K, a 106% increase from the prior year. The company attributes this growth to an uptick in product sales and ongoing airport security services. Despite a net loss of $(2,599K) for the quarter, financial metrics indicate operational improvements. The company received $1.5 million from a federal funding program to support growth and has consolidated its credit facilities to enhance liquidity. CEO Sean Krakiwsky expressed confidence in future growth, driven by increased demand for its 100 MHz NMR product and the CATSA contract.

Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) will hold a conference call on November 29, 2022, at 5:00 PM ET to discuss third-quarter results for the period ending September 30, 2022. CEO Sean Krakiwsky and Interim CFO Randall McRae will lead the call. A European Q&A session is scheduled for November 30, 2022, at 8:30 AM ET. Investors can participate through a live webcast or by phone. Nanalysis specializes in portable Nuclear Magnetic Resonance devices for various industries and continues to expand its product lineup.

Nanalysis Scientific Corp. announced preliminary Q3 2022 revenues expected to exceed $6.8 million, marking a year-over-year growth of over 100%. The company is optimistic about recovery in its core NMR business and anticipates significant billings from its CATSA service contract in Q4 2022. Noteworthy achievements this quarter include record shipments of 20 units of the 100MHz NMR and a C$1.1 million contract for a custom MRI system in France. CEO Sean Krakiwsky will present at the LD Micro Conference on Oct. 25.

Nanalysis Scientific Corp. (NSCIF) has granted 377,500 stock options to employees, including 175,000 to an officer, at $1.10 per share, with a five-year exercise period. The options will vest over three years. This move aims to incentivize employees and align their interests with shareholders. Nanalysis specializes in portable Nuclear Magnetic Resonance (NMR) technology for various industries and has an innovation pipeline that includes a new 100MHz device. The company also broadens its market presence through its recent acquisition of K'Prime and a 43% stake in Quad Systems AG.

Nanalysis Scientific Corp. reported its Q2 2022 results, highlighting a 19% revenue growth year-over-year to $5.187 million, despite a net loss of $2.532 million compared to a net income of $222,000 in Q2 2021. The gross margin decreased from 67% to 62%. The company secured a $160 million service contract with CATSA effective May 25, 2022. Due to operational challenges in scaling its NMR sales, the company is restructuring its sales model and focusing on increasing production capabilities. Nanalysis anticipates revenue growth will improve in the current quarter.

Nanalysis Scientific Corp. will hold a conference call on August 25, 2022, at 5:00 PM ET to discuss its second-quarter financial results for the period ending June 30, 2022. CEO Sean Krakiwsky and Interim CFO Randall McRae will lead the discussion. Investors can participate by phone or through a live webcast. A follow-up Q&A session for European investors is scheduled for August 26 at 8:30 AM ET. Nanalysis specializes in portable NMR technology for various industries and recently expanded its product offerings with advanced devices.

Nanalysis Scientific Corp. announced a management transition on July 21, 2022, with CFO Luke Caplette stepping down but remaining as a part-time consultant. Corporate Controller Randall McRae has been appointed as interim CFO. The company appreciates Caplette's contributions and expresses confidence in McRae’s experience and leadership during this transition. McRae brings over 15 years of experience, having worked with MNP LLP/Deloitte LLP and co-founded a cloud accounting firm. Nanalysis focuses on developing portable Nuclear Magnetic Resonance spectrometers for various industries.